What is EXEL's current stock price?

As of now, EXEL is trading at $38.72, with a daily change of +1.88%.

What are the risks associated with EXEL stock?

EXEL Key risk is its Low Risk Level, .

What is EXEL next earnings date?

EXEL next earnings report is scheduled for Oct 28, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

EXEL Stock Analysis & IQ Rating | Exelixis

EXEL

Exelixis

$38.72

+$0.67 | +1.88%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 49.4

MKT CAP

$ 10.43B

52W Low

$ 27.86

VOL

$ 1.79M

P/E Ratio

18.57

AVG VOL

$ 2.84M

RSI

50.30

TREND

Uptrend

EXEL Stock IQ

Login to see Exelixis (EXEL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

EXEL Target Price

Login to display

Strengths

EXEL Rewards

Trading below its fair value

EXEL Rewards

Upgraded on attractively valued

EXEL Rewards

Outperform the market

Risk Analysis

EXEL Risk Analysis

Earnings are forecast to decrease

Chart

$40.56 (-4.54%)

$37.26 (+3.92%)

$42.22 (-8.29%)

$35.8 (+8.16%)

1year

6month

3month

1month

EXEL Risk Level

EXEL has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

EXEL Analysts Opinion

EXEL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

EXEL Analysts Opinion

EXEL Analysts opinion is positive and also has improved from the past 3 months

EXEL Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

60%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

20%

86%

EXEL Street Opinion

EXEL Street view is bullish and have positive views on the near-term outlook

EXEL Performance Sentiment

Sentiments overview associated with EXEL events and the stock performance.

60%

35%

Positive

Negative

12 out of 20
events present

7 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$37.14

Resistance
Price

$34.30

Current Price Range

$41.35

Show methods +

EXEL Earnings

The TTM reflects 12-month period, providing review of EXEL financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

2,230

2,169

1,830

+10.39%

Cost of Revenue

76

73

+2.03%

Gross Profit

2,154

2,092

1,758

+10.69%

Operating Exp

1,402

1,403

1,587

-6.01%

Operating Inc

752

690

171

+109.71%

Net Interest Inc

76

77

87

-6.54%

Interest Exp

-

Interest Inc

76

77

87

-6.54%

Other Inc Exp

-52

-85

-

EPS Growth

2.16

1.80

0.65

+82.29%

EXEL Financial Health

The company financial health has moderately improved over the past year

Financial Score

4.09

Next Earnings Date: Oct 28, 2025

Linked to EXEL

IQ

Close Price

Change

RVMD

4.16

54.51

+1.95%

BNTX

3.64

105.66

+0.87%

AMGN

3.99

292.20

-0.39%

AGEN

3.50

4.16

-0.96%

EXEL Latest Analysis +

Leerink Partners Upgrades Exelixis (EXEL). Fintel reports that on October 21 2025 Leerink Partners upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Market Perform to Outperform. Analyst Price Forecast Suggests 30.87% Upside

Tue Oct 21, 2025

$36.13 | +4.60%

Potential

Rating

Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results. We recently published 10 Stocks With Massive Losses. AI Stocks Not Spared. Exelixis Inc. (NASDAQ:EXEL) is one of the worst performers on Monday. Exelixis tumbled by 12 percent on Monday to close at $34.54 apiece as unimpressed investors soured on the results of its phase 3 trial for the study of Zanzalintinib for colon cancer. [….]

Tue Oct 21, 2025

$36.13 | +4.60%

Momentum

Potential

Top 3 Health Care Stocks Youll Regret Missing In October. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator which compares a stock’.s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’.s price action it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below

Tue Oct 21, 2025

$36.13 | +4.60%

Potential

Technical

Validea John Neff Strategy Daily Upgrade Report - 10/21/2025. The following are todays upgrades for Valideas Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.EXELIXIS INC (EXEL) is

Tue Oct 21, 2025

$36.13 | +4.60%

Earnings

Potential

Rating

Exelixis Enters Oversold Territory (EXEL). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me

Mon Oct 20, 2025

$34.30 | -12.00%

Technical

Exelixis shares fall after mixed cancer trial results.

Mon Oct 20, 2025

$34.30 | -12.00%

Earnings

Momentum

The Ultimate Biotech Stock to Buy With $50 Right Now. Key PointsShares of mid-cap oncology specialist Exelixis are worth about $39 each right now.

Tue Oct 14, 2025

$39.51 | +2.78%

Potential

EXEL Makes Notable Cross Below Critical Moving Average. In trading on Thursday shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $38.49 changing hands as low as $38.27 per share. Exelixis Inc shares are currently trading off about 0.2% on the day. The chart below shows the one year performance of

Thu Oct 9, 2025

$38.57 | -0.18%

Technical

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Thu Oct 9, 2025

$38.57 | -0.18%

Potential

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Wed Oct 8, 2025

$38.64 | -2.50%

Momentum

FAQ About EXEL Stock Insights

What is EXEL current stock price?

What are EXEL stock strengths?

What risks are associated with EXEL stock?

When is EXEL next earnings report?

What is EXEL market cap and volume?

What is EXEL's current Stock IQ?

Should I buy EXEL stock right now?

Is EXEL a Strong Buy right now?

What does a 'Strong Buy' rating mean for EXEL?

What does a 'Strong Sell' rating mean for EXEL?

What factors influence EXEL's Stock IQ?

Explore our EXEL Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored EXEL Stock Strategies
Effective Risk Management

FIND US ON

Receive our EXEL Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

EXEL

Exelixis

Current Price

$38.72

+$0.67 | +1.88%

52W High

$ 49.4

MKT CAP

$ 10.43B

52W Low

$ 27.86

VOL

$ 1.79M

P/E Ratio

18.57

AVG VOL

$ 2.84M

RSI

50.30

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

EXEL Rewards

Trading below its fair value

EXEL Rewards

Upgraded on attractively valued

EXEL Rewards

Outperform the market

Risk Analysis

EXEL Risk Analysis

Earnings are forecast to decrease

Linked to EXEL

Symbol

IQ

Close

Change

RVMD

4.16

54.51

+1.95%

BNTX

3.64

105.66

+0.87%

AMGN

3.99

292.20

-0.39%

AGEN

3.50

4.16

-0.96%

EXEL Stock IQ

Login to unlock Exelixis (EXEL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$40.56 (-4.54%)

$37.26 (+3.92%)

$42.22 (-8.29%)

$35.8 (+8.16%)

1year

6month

3month

1month

EXEL Analysts Opinion

EXEL Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

EXEL Analysts Opinion

EXEL Analysts opinion is positive and also has improved from the past 3 months

EXEL Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

60%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

20%

86%

EXEL Street Opinion

EXEL Street view is bullish and have positive views on the near-term outlook

EXEL Risk Level

EXEL has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

EXEL Performance Sentiment

Sentiments overview associated with EXEL events and the stock performance.

60%

35%

Positive

Negative

12 out of 20
events present

7 out of 20
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$37.14

Resistance
Price

$34.30

Current Price Range

$41.35

Show methods +

EXEL Earnings

The TTM data reflects the most recent 12-month period, providing overview of EXEL financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

2,230

2,169

1,830

+10.39%

Cost of Revenue

76

73

+2.03%

Gross Profit

2,154

2,092

1,758

+10.69%

Operating Exp

1,402

1,403

1,587

-6.01%

Operating Inc

752

690

171

+109.71%

Net Interest Inc

76

77

87

-6.54%

Interest Exp

-

Interest Inc

76

77

87

-6.54%

Other Inc Exp

-52

-85

-

EPS Growth

2.16

1.80

0.65

+82.29%

EXEL Financial Health

The company financial health has moderately improved over the past year

Financial Score

4.09

Next Earnings Date: Oct 28, 2025

EXEL Latest Analysis

Leerink Partners Upgrades Exelixis (EXEL). Fintel reports that on October 21 2025 Leerink Partners upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Market Perform to Outperform. Analyst Price Forecast Suggests 30.87% Upside

Tue Oct 21, 2025

$36.13 | +4.60%

Potential

Rating

Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results. We recently published 10 Stocks With Massive Losses. AI Stocks Not Spared. Exelixis Inc. (NASDAQ:EXEL) is one of the worst performers on Monday. Exelixis tumbled by 12 percent on Monday to close at $34.54 apiece as unimpressed investors soured on the results of its phase 3 trial for the study of Zanzalintinib for colon cancer. [….]

Tue Oct 21, 2025

$36.13 | +4.60%

Momentum

Potential

Top 3 Health Care Stocks Youll Regret Missing In October. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator which compares a stock’.s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’.s price action it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below

Tue Oct 21, 2025

$36.13 | +4.60%

Potential

Technical

Validea John Neff Strategy Daily Upgrade Report - 10/21/2025. The following are todays upgrades for Valideas Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.EXELIXIS INC (EXEL) is

Tue Oct 21, 2025

$36.13 | +4.60%

Earnings

Potential

Rating

Exelixis Enters Oversold Territory (EXEL). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me

Mon Oct 20, 2025

$34.30 | -12.00%

Technical

Exelixis shares fall after mixed cancer trial results.

Mon Oct 20, 2025

$34.30 | -12.00%

Earnings

Momentum

The Ultimate Biotech Stock to Buy With $50 Right Now. Key PointsShares of mid-cap oncology specialist Exelixis are worth about $39 each right now.

Tue Oct 14, 2025

$39.51 | +2.78%

Potential

EXEL Makes Notable Cross Below Critical Moving Average. In trading on Thursday shares of Exelixis Inc (Symbol: EXEL) crossed below their 200 day moving average of $38.49 changing hands as low as $38.27 per share. Exelixis Inc shares are currently trading off about 0.2% on the day. The chart below shows the one year performance of

Thu Oct 9, 2025

$38.57 | -0.18%

Technical

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Thu Oct 9, 2025

$38.57 | -0.18%

Potential

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Wed Oct 8, 2025

$38.64 | -2.50%

Momentum

Discover EXEL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of EXEL. We're here to help you make informed investment decisions today.

FIND US ON

Receive our EXEL Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

EXEL Stock trends

EXEL Stock performance

EXEL Stock analysis

EXEL investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EXEL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EXEL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

EXEL Stock Analysis & IQ Rating | Exelixis

EXEL Stock IQ

EXEL Target Price

EXEL Risk Level

EXEL Analysts Opinion

EXEL Street Consensus

EXEL Performance Sentiment

Technical Price Levels

EXEL Financial Health

Explore our EXEL Stock insights

Receive our EXEL Daily Alerts

EXEL Stock IQ

EXEL Street Consensus

EXEL Risk Level

Technical Price Levels

Discover EXEL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of EXEL. We're here to help you make informed investment decisions today.

Receive our EXEL Daily Alerts

EXEL Runner Alarm